[19] Long-term medical management includes the use of diazoxide, somatostatin analogs, nifedipine, glucagon, recombinant IGF-I, glucocorticoids, human growth hormone, dietary intervention, or combinations of these therapies
Future studies should include dedicated rhythm endpoints and continuous monitoring strategies
Dosing is small and personalized
But in those with a high-risk family or personal history, we are typically much more guarded." Another concern
Additional concerns, as reported by the FDA, include compounding multiple GLP1 receptor agonists together leading to serious side effects
These prescription drugs mimic the effects of hormones in the body that regulate blood sugar levels and appetite